Ethanol extract of Pharbitis nil ameliorates liver fibrosis through regulation of the TGFβ1-SMAD2/3 pathway
- 11 May 2022
- journal article
- research article
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 294, 115370
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science, ICT and Future Planning (2021M3H9A1097551)
- National Research Foundation of Korea
- Ministry of Education (2020R1A6A1A0304370812)
This publication has 38 references indexed in Scilit:
- DA-9701: A New Multi-Acting Drug for the Treatment of Functional DyspepsiaBiomolecules & Therapeutics, 2013
- TGF-β in progression of liver diseaseCell and tissue research, 2011
- Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and AdolescentsJAMA, 2011
- Mechanisms of hepatic fibrogenesisBest Practice & Research Clinical Gastroenterology, 2011
- Histopathological diagnosis of non-alcoholic and alcoholic fatty liver diseaseVirchows Archiv, 2011
- Silymarin use and liver disease progression in the Hepatitis C Antiviral Long‐Term Treatment against Cirrhosis trialAlimentary Pharmacology & Therapeutics, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Diterpene Glycosides from the Seeds of Pharbitis nilJournal of Natural Products, 2009
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003
- Activation of hepatic stellate cells - a key issue in liver fibrosisFrontiers in Bioscience-Landmark, 2002